The European Commission Approves Alnylam's AMVUTTRA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 1,634,923 | $441,461,908 | +12% | 2.53% |
| 2. | AQR Capital Management Cliff Asness | 828,344 | $217,026,079 | +2% | 0.22% |
| 3. | 110,000,000 | $126,865,310 | 2.5% | ||
| 4. | OrbiMed Advisors Samuel Isaly | 346,100 | $93,453,922 | -17% | 2.23% |
| 5. | 74,000,000 | $85,478,880 | -8% | 3.46% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | $1,210.68 | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | $9,152.00 | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | $21,381,396.87 | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | $751,502.00 | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | $1,032,327.90 | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $306.00 | 19,297 | $5,904,882.00 | 48,948 | 2025-06-02 | Filing | |
| $306.00 | 6,171 | $1,888,326.00 | 48,948 | 2025-05-30 | Filing | |
| $304.00 | 25,469 | $7,742,576.00 | 55,119 | 2025-05-30 | Filing | |
| $283.83 | 1,617 | $458,953.11 | 16,804 | 2025-05-15 | Filing | |
| $282.81 | 1,728 | $488,695.68 | 18,421 | 2025-05-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,749,623 | $4,522,698,635 | 0.73% | |
| 2. | 15,309,860 | $4,133,968,399 | 0.26% | |
| 3. | 13,056,605 | $3,525,544,482 | 0.06% | |
| 4. | 9,559,382 | $2,581,224,460 | 0.05% | |
| 5. | 7,154,728 | $1,931,903,727 | 0.42% |
News See All
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Alnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. Wainwright
On June 2, H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his price target from $400 to $500.
12 Best Growth Stocks to Buy and Hold for the Long Term
The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call. At this time, all lines are in a listen-only mode.
10 Best Growth Stocks to Buy According to Billionaires
The stock market has been on a rollercoaster ride for the past few weeks as the sentiment has quickly shifted from post-election bullishness to being priced in for a slow-down or a recession.
10 Best Long Term Growth Stocks to Buy According to Billionaires
As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, immigration, and global geopolitics, resulting in elevated levels of uncertainty and...
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript February 13, 2025Alnylam Pharmaceuticals, Inc. misses on earnings expectations.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Billionaire Hedge Funds
